Federal government announces positive changes to drug pricing regulations

August 9, 2019

Canada’s unions applaud today’s announcement by the federal government of new measures updating Canada’s drug-pricing regulations.

“Many life-saving medicines are unaffordable. This new framework will better protect Canadians from skyrocketing drug prices by lowering the cost of brand name medicines,” said CLC President Hassan Yussuff. “This is a good step towards a universal public pharmacare program in Canada.”

Canada currently compares prices with the US and Switzerland—two countries with some of the world’s highest drug prices—when setting its maximum prices for patented drugs. These new regulations no longer require consideration of US and Swiss pricing, instead allowing the Patented Medicine Prices Review Board (PMPRB) to set maximum prices for patented drugs based on other countries with economies and health-care systems similar to Canada.

The updated framework also provides better reporting on drug prices including list prices and discounts offered to third parties like insurance companies. The PMPRB will also have the authority to determine whether drug prices correspond to value to patients and to the healthcare system.

The existing framework used by the PMPRB has not adequately protected Canadians from excessively high prices for patented medicines over the last 30 years. Since 1987, prescription drug costs in Canada have increased at an average annual rate of 7.3%, or over 3 times the inflation rate.

“Canadians have been paying some of the highest prices for patented medicines in the world because the old regulations allowed big pharmaceutical companies to set their prices based on market evaluations, and not on what individuals could actually afford,” said Yussuff.

“Big pharmaceutical companies have continued to renege on their promises to invest 10% of sales in research and development each year, and to introduce new drugs that had substantial or breakthrough therapeutic benefit to Canadians,” said Yussuff.

In 2017, the investment of big pharmaceutical companies was the lowest it has ever been in 30 years—a paltry 4.6%—and nine-in-ten new-patented medicines offered slight or no improvement in therapeutic benefit over existing therapies.

Tags: Pharmacare

Related Articles

Universal pharmacare should be an easy pill to swallow

By Hassan Yussuff, as published in the Toronto Sun. Finally, some good news for the millions of Canadians who have to choose between paying for groceries or their prescription medications. Canada’s Advisory Council on the Implementation of National Pharmacare has laid out a clear path for public, single-payer, universal pharmacare in its final report. “The time for universal, single-payer, public…
Read More

Canada’s unions say pharmacare council gets it right, now governments must act

Canada’s unions are applauding the recommendation made by the Advisory Council on the Implementation of National Pharmacare for the adoption of a public, universal and single-payer plan for prescription drug coverage across Canada. “Universal pharmacare will fundamentally improve the lives of all Canadians and, with this report, we finally have a blueprint for completing the medicare system Canada first adopted…
Read More

Time for Pride celebration, and resistance to attacks on human rights, say Canada’s unions

As Pride events are held in communities across the country, Canada’s unions are celebrating the achievements of LGBTQ2SI activism from coast to coast, while committing to challenging the rise of racism and hate politics threatening human rights around the world. “Pride season is an important moment to come together and celebrate the victories and visibility of LGBTQ2SI activism in our…
Read More